1.Improvement of Erdheim-Chester disease-related renal failure after treatment with anakinra.
Manuel Alfredo PODESTA ; Giorgio GRAZIANI ; Francesco REGGIANI ; Michele BUEMI ; Salvatore BADALAMENTI ; Claudio PONTICELLI
Kidney Research and Clinical Practice 2014;33(3):165-167
Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis characterized by infiltrates of lipid-laden CD68+/CD1- histiocytes, affecting heart, lungs, central nervous system, and bones. Kidney and adjacent structures can also be affected, leading to renal failure in about 30% of cases. The diagnosis is challenging, and treatment is generally based on administration of interferon-alpha (IFNalpha), but preliminary results also showed the therapeutic efficacy of anakinra, an antagonist of the receptor of interleukin-1 (IL-1). We report the case of an elderly patient with ECD and severe involvement of the heart and kidneys who was successfully treated with anakinra.
Aged
;
Central Nervous System
;
Diagnosis
;
Erdheim-Chester Disease
;
Heart
;
Histiocytes
;
Histiocytosis
;
Humans
;
Interferon-alpha
;
Interleukin 1 Receptor Antagonist Protein*
;
Interleukin-1
;
Kidney
;
Lung
;
Renal Insufficiency*